CD5L 构成整合肝脏甲状腺激素作用的新型生物标志物
研究利用人与小鼠实验性甲状腺毒症血浆多组学数据寻找甲状腺激素功能标志物,发现16种血浆蛋白在甲状腺素治疗下与甲状腺功能正常对照相比一致性差异丰富,主要来源于肝、脾和骨;临床队列及多种小鼠模型确认CD5L为不同血清甲状腺激素状态和治疗周期下最稳健的候选标志物,其由促炎M1巨噬细胞产生并受TRα1和TRβ两种异构体依赖的间接机制调控。
要点
- 甲状腺毒症血浆多组学发现16种蛋白在甲状腺素治疗下与甲状腺功能正常对照相比一致性差异丰富。
- CD5L在不同血清甲状腺激素状态和治疗周期中均为最稳健的候选生物标志物。
- CD5L来源于促炎M1巨噬细胞,其表达调控依赖TRα1和TRβ两种异构体。
核心结论
- 研究结果识别了若干血清中甲状腺激素作用的新靶点,其中CD5L为最稳健的标志物。
- 作者认为虽需进一步研究验证这些靶点的特异性,CD5L似乎是评估肝细胞-巨噬细胞交互中甲状腺激素作用的有前景候选标志物。
研究设计与样本
- 利用人与小鼠实验性甲状腺毒症血浆无靶向多组学数据识别可能的甲状腺激素功能生物标志物。
- 后续小鼠研究用于确定组织来源及两种甲状腺激素受体(TR)的参与。
- 使用原代小鼠细胞对潜在细胞机制进行深入表征。
- 在临床队列和不同小鼠模型中进行独立研究验证候选标志物。
主要发现
- 血浆蛋白质组数据分析显示,甲状腺素治疗下与甲状腺功能正常对照相比,两个物种间一致性差异丰富的血浆蛋白有16种,主要来源于肝、脾和骨。
- 临床队列和不同小鼠模型的独立研究确认CD5L在不同血清甲状腺激素状态和治疗周期下为最稳健的候选生物标志物。
- 体外研究显示CD5L来源于促炎M1巨噬细胞,类似于肝脏驻留的Kupffer细胞,并受一种需要肝细胞分泌未知因子的间接机制调控。
- 体内Cd5l表达的调控依赖TRα1和TRβ两种异构体,与TRα1在免疫细胞中的作用及TRβ依赖的肝细胞来源信号一致。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出需要进一步研究验证这些靶点的特异性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Pathological conditions of the thyroid hormone (TH) system are routinely diagnosed by using serum concentrations of thyrotropin (TSH), which is sufficient in most cases. However, in certain conditions, such as resistance to TH due to mutations in THRB (RTHb) or TSH-releasing pituitary adenoma (TSHoma), TSH may be insufficient for a correct diagnosis, even in combination with serum TH concentrations. Likewise, under TH replacement therapy, these parameters can be misleading and do not always allow optimal treatment. Hence, additional biomarkers to assess challenging clinical conditions would be highly beneficial. Methods: Data from untargeted multi-omics analyses of plasma samples from experimental thyrotoxicosis in human and mouse were exploited to identify proteins that might represent possible biomarkers of TH function. Subsequent mouse studies were used to identify the tissue of origin and the involvement of the two different TH receptors (TR). For in-depth characterization of the underlying cellular mechanisms, primary mouse cells were used. Results: The analysis of the plasma proteome data sets revealed 16 plasma proteins that were concordantly differentially abundant under thyroxine treatment compared with euthyroid controls across the two species. These originated predominantly from liver, spleen, and bone. Independent studies in a clinical cohort and different mouse models identified CD5L as the most robust putative biomarker under different serum TH states and treatment periods. In vitro studies revealed that CD5L originates from proinflammatory M1 macrophages, which are similar to liver-residing Kupffer cells, and is regulated by an indirect mechanism requiring the secretion of a yet unknown factor from hepatocytes. In agreement with the role of TRα1 in immune cells and the TRβ-dependent hepatocyte-derived signaling, the in vivo regulation of Cd5l expression depended on both TR isoforms. Conclusion: Our results identify several novel targets of TH action in serum, with CD5L as the most robust marker. Although further studies will be needed to validate the specificity of these targets, CD5L seems to be a promising candidate to assess TH action in hepatocyte-macrophage crosstalk.
引用
- Nock S, Johann K, Harder L, et al. CD5L Constitutes a Novel Biomarker for Integrated Hepatic Thyroid Hormone Action. Thyroid. 2020. PMID: 32183611. doi:10.1089/thy.2019.0635
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。